Scientific Sessions 2024  /  Annual Lipid Updates - 2024  /  New Frontiers in Triglyceride Lowering
Logo

American Heart Association

  112
  0

Final ID:

New Frontiers in Triglyceride Lowering

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
  • Remaley, Alan T  ( NIH , Bethesda , Maryland , United States )
  • Cariou, Bertrand  ( CHU Nantes , Nantes Cedex 1 , France )
  • Hudgins, Lisa  ( The Rogosin Institute , New York , New York , United States )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now) | Alan T Remaley: No Answer | Bertrand Cariou: DO have relevant financial relationships ; Advisor:Novartis:Active (exists now) ; Advisor:Ultragenyx:Past (completed) ; Speaker:Amgen:Past (completed) ; Advisor:MSD:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Novo-Nordisk:Active (exists now) ; Speaker:Astra-Zeneca:Past (completed) ; Speaker:Sanofi:Active (exists now) ; Research Funding (PI or named investigator):Sanofi:Past (completed) | Lisa Hudgins: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Annual Lipid Updates - 2024

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Controversies in Nutrition and Lipids

Anderson Cheryl, Polonsky Tamar

New and Emerging Targets for Lowering LDL-Cholesterol and Triglycerides: ANGPTL3, CETP, APOC-III

Kastelein John, Ray Kausik

More abstracts from these authors:
Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial

Asprusten Emil, Licka Manuela, Cariou Bertrand, Vest Jeff, Kallend David, Stein Evan

Targeting triglyceride-rich lipoproteins: Beyond fibrates and fish oils

Cariou Bertrand, Hobbs Helen, Boren Jan

You have to be authorized to contact abstract author. Please, Login
Not Available